CLAIMS

What is claimed:

1. Use of a pharmaceutically acceptable amount of a first composition in the manufacture of a first medicament and use of a pharmaceutically acceptable amount of a second composition in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy for the treatment and/or prevention of HIV infection in a mammal, wherein

the first composition comprises a nucleic acid sequence of a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7 comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the nucleic acid sequence further comprises a promoter sequence linked to a sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag,

the second composition comprises another nucleic acid sequence of a chimpanzee-derived adenovirus vector of serotype AdC6 or AdC7 comprising an early gene E3 wherein the ORF3, ORF4, ORF5, ORF6, and ORF7 are deleted, wherein the early gene E1 is deleted, and wherein the another nucleic acid sequence further comprises a promoter sequence linked to a sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140, gp160 and Gag, and

the first and second compositions have different serotypes selected from the group consisting of AdC6 and AdC7.

2. The use according to claim 1, wherein the first composition and the second composition comprise the same or a different HIV heterologous protein selected from the group consisting of gp140, gp160, and Gag.

3. The use according to claim 1, wherein the first and second medicaments generate an adaptive B cell immune response to the heterologous protein of the first composition in the mammal.

4. The use according to claim 1, wherein the first and second medicaments generate an effector and memory T cell immune response to the heterologous protein of the first composition in the mammal.

5. The use according to any one of claims 1-4, wherein the mammal is a human.

6. The use according to any one of claims 1-5, wherein the promoter is
(i) a constitutive promoter; or
(ii) a cytomegalovirus immediate early promoter (CMV).

7. The use according to any one of claims 1-6, wherein the nucleic acid sequence of the first composition and the another nucleic acid sequence of the second composition are selected from the group consisting of SEQ ID NOs: 1-8.